

10/3,K,AB/16 (Item 1 from file: 340)
DIALOG(R) File 340:CLAIMS(R)/US Patent
(c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 2087080 IFI Acc No: 9022843

Document Type: C

USE OF TUMOR NECROSIS FACTOR (TNF) AS AN **ADJUVANT**;
IMMUNOLOGICAL RESPONSE

Inventors: Shepard H Michael (US); Talmadge James E (US)

Assignee: Genentech Inc

Assignee Code: 07579

Publication (No,Date), Applic (No,Date):

US 4963354 19901016 US 877075 19870121

Publication Kind: A

Calculated Expiration: 20071016

(Cited in 022 later patents)

Priority Applic(No,Date): US 877075 19870121

Abstract: Tumor necrosis factors, alone or together with cytokines such as IL-1 or INF- gamma , are capable of serving as non-toxic vaccine adjuvants.

USE OF TUMOR NECROSIS FACTOR (TNF) AS AN **ADJUVANT**

? s photodynamic or phototherapy
19046 PHOTODYNAMIC
8768 PHOTOTHERAPY
S1 27360 PHOTODYNAMIC OR PHOTOTHERAPY
? s immunologic(5n) adjuvant
205130 IMMUNOLOGIC
116000 ADJUVANT
S2 526 IMMUNOLOGIC(5N) ADJUVANT
? s s1 and s2
27360 S1
526 S2
S3 1 S1 AND S2
? t s3/3,k,ab/1

3/3,K,AB/1 (Item 1 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent
(c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10060546 IFI Acc No: 2002-0004053 IFI Acc No: 2002-0000935
Document Type: C

CELLULAR OR ACCELLULAR ORGANISM ERADICATION VIA **PHOTODYNAMIC**
ACTIVATION OF A CELLULAR OR ACCELLULAR ORGANISM SPECIFIC IMMUNOLOGICAL
RESPONSE; IDENTIFYING A CELLULAR/ACELLULAR ORGANISM SITE ON LIVING BODY
AND COMBINING ADMINISTRATION OF ADJUVANT WHICH INCREASES IMMUNE RESPONSE
(BUILDS ANTIBODIES) AND **PHOTODYNAMIC** LIGHT CAUSING NECROSIS

Inventors: Biel Merrill A (US)

Assignee: Unassigned Or Assigned To Individual

Assignee Code: 68000

Publication (No,Date), Applic (No,Date):

US 20020004053 20020110 US 2001782841 20010214

Publication Kind: A1

Cont.-in-part Pub(No),Applic(No,Date): PENDING US

98139861 19980825

Priority Applic(No,Date): US 2001782841 20010214; US 98139861 19980825

Abstract: A method of eradicating cellular or acellular organisms of a living body by promoting a systemic immunologic activity specific to the cellular/acellular organisms including the steps identifying a cellular/acellular organism site of the living body; combining an administration of an **immunologic adjuvant** to said body, the **immunologic adjuvant** promoting a systemic increased level of molecular and cellular factors and cells necessary to effect a systemic immunologic response and an administration of a **photodynamic** light therapy proximate said cellular/acellular organism site, said **photodynamic** light therapy having a sufficient light dosage to cause cell necrosis of a cellular/acellular organism within the cellular/acellular organism site, said **photodynamic** cellular/acellular organism necrosis resulting in the release of necrosis-generated cellular/acellular organism antigens; and promoting and enhancing a systemic cellular/acellular organism-related immunologic response of said body as a result of an interaction between the molecular and cellular factors and cells and the necrosis-generated cellular/acellular organism specific antigens, said systemic immunologic response yielding an increased level of cellular/acellular organism specific antibodies and other immunologic cellular/acellular organism specific products and cells specifically targeted to immunologically eradicate similar cellular/acellular organisms.

CELLULAR OR ACCELLULAR ORGANISM ERADICATION VIA **PHOTODYNAMIC**
ACTIVATION OF A CELLULAR OR ACCELLULAR ORGANISM SPECIFIC IMMUNOLOGICAL
RESPONSE...

...ON LIVING BODY AND COMBINING ADMINISTRATION OF ADJUVANT WHICH INCREASES IMMUNE RESPONSE (BUILDS ANTIBODIES) AND PHOTODYNAMIC LIGHT CAUSING NECROSIS

Abstract: ...identifying a cellular/acellular organism site of the living body; combining an administration of an **immunologic adjuvant** to said body, the **immunologic adjuvant** promoting a systemic increased level of molecular and cellular factors and cells necessary to effect a systemic immunologic response and an administration of a **photodynamic** light therapy proximate said cellular/acellular organism site, said **photodynamic** light therapy having a sufficient light dosage to cause cell necrosis of a cellular/acellular organism within the cellular/acellular organism site, said **photodynamic** cellular/acellular organism necrosis resulting in the release of necrosis-generated cellular/acellular organism antigens...

Exemplary Claim: ...identifying a primary tumor tissue site of the living body; combining an administration of an **immunologic adjuvant** at a predetermined concentration to said body, said predetermined concentration being approximately a standard concentration for immunization procedures of said body, said administered **immunologic adjuvant** resulting in a systemic condition of heightened nonspecific enhanced immune system of the body, including...

...of nonspecific immune-related molecular and cellular factors and cells, and an administration of a **photodynamic** light therapy proximate said primary tumor tissue site, said **photodynamic** light therapy having a light wavelength and a sufficient light dosage to eradicate tumor cells...

...between the increased level of nonspecific immune-related molecular and cellular factors and cells and **photodynamic** light therapy released tumor cell specific antigens, said systemic immunologic response yielding increased levels of...

Non-exemplary Claims: ...4. The method of claim 1 wherein the administration of the **immunologic adjuvant** is achieved via one or more of the group containing an intravenous injection, an injection...

...5. The method of claim 1 wherein the step of administering the **photodynamic** light therapy includes the step of administering a photosensitizing agent...

...7. The method of claim 1 wherein the **immunologic adjuvant** is DETOX...

...9. The method of claim 1 wherein the administration of the **immunologic adjuvant** precedes the administration of the **photodynamic** light therapy...

...10. The method of claim 1 wherein the administration of the **photodynamic** light therapy precedes the administration of the **immunologic adjuvant**.

...

...11. The method of claim 1 wherein the administration of the **photodynamic** light therapy and the administration of the **immunologic adjuvant** occur at least in part simultaneously

...

...12. The method of claim 1 wherein the administration of the **immunologic adjuvant** includes one or more separate administrations of the adjuvant to the body...

...13. The method of claim 1 wherein the administration of the **immunologic adjuvant** includes administrations before and after the administration of the **photodynamic** light therapy...

...administering of an immune modulator to the body before, during, or after the administration of **photodynamic** light therapy...of: identifying an acellular organism site of the living body; combining an administration of an **immunologic adjuvant** to said body, said **immunologic adjuvant** promoting a systemic increased level of molecular and cellular factors and cells necessary to effect a systemic immunologic response and an administration of a **photodynamic** light therapy proximate said acellular organism site, said **photodynamic** light therapy having a sufficient light dosage to cause cell necrosis of an acellular organism within the acellular organism site, said **photodynamic** acellular organism necrosis resulting in the release of necrosis-generated acellular organism antigens; and promoting...

...17. The method of claim 16 wherein the administration of the **immunologic adjuvant** precedes the administration of the **photodynamic** light therapy...

...18. The method of claim 16 wherein the administration of the **photodynamic** light therapy precedes the administration of the **immunologic adjuvant**.

...19. The method of claim 16 wherein the administration of the **photodynamic** light therapy and the administration of the **immunologic adjuvant** occur at least in part simultaneously

...

...22. The method of claim 16 wherein the administration of the **immunologic adjuvant** is achieved via one or more of the group containing an intravenous injection, an injection...

...23. The method of claim 16 wherein the step of administering the **photodynamic** light therapy includes the step of administering a photosensitizing agent...

...25. The method of claim 16 wherein the **immunologic adjuvant** is DETOX26. The method of claim 16 further comprising the step of: administering the **immunologic adjuvant** to the body for a period of time following the **photodynamic** light therapy...

...The method of claim 16 further comprising the step of: repeating the administrations of the **photodynamic** light therapy...

...The method of claim 16 further comprising the step of: repeating the administrations of the **immunologic adjuvant**.

...

...administering of an immune modulator to the body before, during, or after the administration of **photodynamic** light therapy...

...of: identifying a cellular organism site of the living body; combining an administration of an **immunologic adjuvant** to said body, said **immunologic adjuvant** promoting a systemic increased level of molecular and cellular factors and cells necessary to effect a systemic immunologic response and an administration of a **photodynamic** light therapy proximate said cellular organism site, said **photodynamic** light therapy having a sufficient light dosage to cause cell necrosis of a cellular organism within the cellular organism site, said **photodynamic** cellular organism necrosis resulting in the release of necrosis-generated cellular organism

antigens; and promoting...

...34. The method of claim 33, wherein the administration of the **immunologic adjuvant** precedes the administration of the **photodynamic light therapy**...

...35. The method of claim 33, wherein the administration of the **photodynamic light therapy** precedes the administration of the **immunologic adjuvant**.

...

...36. The method of claim 33, wherein the administration of the **photodynamic light therapy** and the administration of the **immunologic adjuvant** occur at least in part simultaneously

...

...37. The method of claim 33 wherein the administration of the **immunologic adjuvant** is achieved via one or more of the group containing an intravenous injection, an injection...39. The method of claim 33 further comprising the step of: administering the **immunologic adjuvant** to the body for a period of time following the **photodynamic light therapy**...

...The method of claim 33 further comprising the step of: repeating the administrations of the **photodynamic light therapy**...

...The method of claim 33 further comprising the step of: repeating the administrations of the **immunologic adjuvant**.

...

...administering of an immune modulator to the body before, during, or after the administration of **photodynamic light therapy**

?